Moleculin Biotech, Inc. MBRX
6.83 USD -0.31 (-4.34%)
Regular-session close
6.98 +0.15 +2.20%
After hours · Nov 17, 4:00 PM ET
6.81 Day range 7.50
3.22 52-week range 227.00
- YTD
- +106.34%
- 1 year
- -35.57%
News
benzinga.com Moleculin Biotech Completes Treatment Of All 90 Patients In Part A Of Pivotal Phase 2/3 MIRACLE Trial For Annamycin In Relapsed/Refractory AML; Comprehensive Data Expected In Q1 2027, With Part B Planned To Begin In H1 2027 - Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML) - Comprehensive Part A data…
benzinga.com Moleculin Biotech Q3 EPS $(9.59) Misses $(8.53) Estimate Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(9.59) per share which missed the analyst consensus estimate of $(8.53) by 12.43 percent. This is a 43.59 percent increase over losses of…
globenewswire.com Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout - Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)benzinga.com Moleculin Biotech And University Of Texas Receive Australian Patent Covering The Preparation Of Preliposomal Annamycin Lyophilizate Australian Patent No. 2020303572 was granted to Moleculin and The Board of Regents of The University of Texas System. The patent titled, "Preparation of Preliposomal Annamycin Lyophilizate,"…
globenewswire.com Moleculin Secures Australian Patent for Annamycin Formulation Technology Patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizatebenzinga.com Moleculin Biotech Reports Preclinical Data Showing Annamycin Plus PD-1 Blockade Extends Survival in Pancreatic Cancer Models Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystanderAnnamycin…
globenewswire.com Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin's antitumor activity, not a bystanderbenzinga.com Moleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AMLMoleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company")
benzinga.com Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
